论文部分内容阅读
目的观察采用沙立度胺联合VAD方案治疗初发多发性骨髓瘤(MM)患者的临床疗效。方法对22例初发MM患者采用沙立度胺联合VAD方案化疗,每21d为1个疗程,1个疗程后间歇4周,观察疗效及药物毒副反应。结果治疗3个疗程后,22例患者部分缓解27.2%(6/22)、进步54.5%(12/22)、总有效率为81.8%(18/22)。毒副反应为骨髓抑制,指端麻木及便秘等。结论沙立度胺联合VAD方案治疗初发MM患者疗效较好,值得临床推广。
Objective To observe the clinical efficacy of thalidomide combined with VAD regimen in the treatment of newly diagnosed multiple myeloma (MM). Methods Twenty-two newly diagnosed MM patients were treated with thalidomide combined with VAD regimen, one course every 21 days. The course of treatment was 4 weeks after one course of treatment. The curative effect and drug toxicity were observed. Results After 3 courses of treatment, 22 patients were partially relieved 27.2% (6/22), 54.5% (12/22) improved, the total effective rate was 81.8% (18/22). Side effects of bone marrow suppression, numbness and constipation and other fingers. Conclusion Thalidomide combined with VAD regimen in the treatment of patients with early onset of MM is effective and worthy of clinical promotion.